Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes

被引:33
作者
Blumenfeld, Andrew M. [1 ]
Silberstein, Stephen D. [2 ]
Dodick, David W. [3 ]
Aurora, Sheena K. [4 ]
Brin, Mitchell F. [5 ,6 ]
Binder, William J. [7 ]
机构
[1] Neurol Ctr, Encinitas, CA USA
[2] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
[3] Mayo Clin, Dept Neurol, Phoenix, AZ USA
[4] Stanford Univ, Dept Neurol, Stanford, CA 94305 USA
[5] Allergan Plc, Irvine, CA USA
[6] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA
[7] Univ Calif Los Angeles, Dept Head & Neck Surg, Los Angeles, CA USA
来源
HEADACHE | 2017年 / 57卷 / 05期
关键词
chronic migraine; onabotulinumtoxinA; injection technique; clinical; TOXIN TYPE-A; TRIGGERED HEMIFACIAL SPASM; PLACEBO-CONTROLLED PHASE; CHRONIC MIGRAINE; BOTULINUM TOXIN; DOUBLE-BLIND; MENINGEAL NOCICEPTORS; ONABOTULINUMTOXINA;
D O I
10.1111/head.13074
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ObjectiveTo provide clinically relevant insights on the identification of the muscles and techniques involved in the safe and effective use of onabotulinumtoxinA for chronic migraine prophylaxis. BackgroundAlthough guidance on the use of onabotulinumtoxinA for chronic migraine is available, based on the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical program, clinical experience has shown that insufficient understanding of the anatomy and function of the head and neck muscles may lead to undesirable outcomes and suboptimal efficacy. Design/MethodsEach muscle involved in the standardized PREEMPT injection paradigm is reviewed with a thorough description of each muscle's anatomy (ie, muscle description and location, innervation, vascular supply) and function. Key insights based on clinical experience are also provided to help improve outcomes. ResultsThe identification of the muscles in the PREEMPT injection paradigm should be based on each patient's unique anatomy and injections should be administered using the advised techniques. A thorough examination of the patient prior to treatment is also critical to determine if any preexisting conditions may increase the risk for unwanted outcomes and appropriate expectations should be communicated. ConclusionsThorough knowledge of the functional anatomy of the muscles involved in the standardized PREEMPT injection paradigm is critical to achieve the efficacy and safety observed in clinical trials. In addition, it is important to assess a patient's baseline condition to anticipate the risk for unwanted outcomes that may result from treatment.
引用
收藏
页码:766 / 777
页数:12
相关论文
共 22 条
[1]  
[Anonymous], SUMMARY PRODUCT CHAR
[2]  
[Anonymous], 2014, CLIN ORIENTED ANATOM
[3]  
[Anonymous], ON INJ INTR INTR INT
[4]  
[Anonymous], BOTOX PROD MON
[5]   OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program [J].
Aurora, S. K. ;
Dodick, D. W. ;
Diener, H. -C. ;
DeGryse, R. E. ;
Turkel, C. C. ;
Lipton, R. B. ;
Silberstein, S. D. .
ACTA NEUROLOGICA SCANDINAVICA, 2014, 129 (01) :61-70
[6]  
Aurora SK, 2010, CEPHALALGIA, V30, P793, DOI 10.1177/0333102410364676
[7]   OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program [J].
Aurora, Sheena K. ;
Winner, Paul ;
Freeman, Marshall C. ;
Spierings, Egilius L. ;
Heiring, Jessica O. ;
DeGryse, Ronald E. ;
VanDenburgh, Amanda M. ;
Nolan, Marissa E. ;
Turkel, Catherine C. .
HEADACHE, 2011, 51 (09) :1358-1373
[8]   Migraine-triggered hemifacial spasm: three new cases [J].
Barahona-Hernando, R. ;
Cuadrado, M. L. ;
Garcia-Ptacek, S. ;
Marcos-de-Vega, A. ;
Jorquera, M. ;
Guerrero, A. ;
Ordas, C. M. ;
Muniz, S. ;
Porta-Etessam, J. .
CEPHALALGIA, 2012, 32 (04) :346-349
[9]   Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study [J].
Binder, WJ ;
Brin, MF ;
Blitzer, A ;
Schoenrock, LD ;
Pogoda, JM .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2000, 123 (06) :669-676
[10]   Procedures for administering botulinum toxin type A for migraine and tension-type headache [J].
Blumenfeld, AM ;
Binder, W ;
Silberstein, SD ;
Blitzer, A .
HEADACHE, 2003, 43 (08) :884-891